JWP24 acetate is the first cell membrane-permeable peptide inhibitor of MAGE-A4, with an IC50 of 200 nM against human MAGE-A4. JWP24 acetate binds to intracellular targets while retaining binding activity, disrupts the interaction between MAGE-A4 and RAD18, and does not induce cytotoxicity at effective concentrations. JWP24 acetate is applicable for cancer-related research [1].
In Vitro, JWP24 (0.005-80 μM; 1.5 h) acetate potently disrupts the interaction between MAGE-A4 and RAD18 in HEK293 cells, with an IC50 of 0.5 μM, and exhibits no cytotoxicity at effective concentrations[1]. JWP24 (10 μM; 2 h) acetate inhibits the interaction between MAGE-A4 and RAD18 in H1299 cell lysates[1].
References:
[1]. Lim J, et al. Development of Next Generation Cell-Permeable Peptide Inhibitors for the Oncological Target MAGE-A4. J Med Chem. 2025;68(18):19377-19395.
In Vitro, JWP24 (0.005-80 μM; 1.5 h) acetate potently disrupts the interaction between MAGE-A4 and RAD18 in HEK293 cells, with an IC50 of 0.5 μM, and exhibits no cytotoxicity at effective concentrations[1]. JWP24 (10 μM; 2 h) acetate inhibits the interaction between MAGE-A4 and RAD18 in H1299 cell lysates[1].
References:
[1]. Lim J, et al. Development of Next Generation Cell-Permeable Peptide Inhibitors for the Oncological Target MAGE-A4. J Med Chem. 2025;68(18):19377-19395.